|
Apr 15
|
Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
|
|
Apr 15
|
Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S
|
|
Apr 14
|
BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.
|
|
Oct 10
|
BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study
|
|
Jul 29
|
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
|
|
Jun 18
|
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
|
|
Jun 17
|
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
|
|
Apr 10
|
BioPorto A/S Appoints Chief Legal Officer
|
|
Jan 9
|
BioPorto implements changes to the Executive Management.
|
|
Dec 9
|
Managers’ transactions
|
|
Dec 8
|
FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)
|
|
Dec 7
|
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
|
|
Dec 4
|
Resignation of Director
|
|
Aug 28
|
BioPorto to Participate in Upcoming Investor Conferences
|